Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 7 of 7
Full-Text Articles in Medicine and Health Sciences
Autoantibodies To The Ny-Eso-1 Tumor Antigen In Metastatic Melanoma: Sialylation Of The Fc Region Of Immunoglobulin G Induces Differential Expression Signatures Of Inflammatory Molecules During Dendritic Cell Differentiation And Maturation, Martin Oaks, Nathaniel Rein, John O. Richards, James Shaffer
Autoantibodies To The Ny-Eso-1 Tumor Antigen In Metastatic Melanoma: Sialylation Of The Fc Region Of Immunoglobulin G Induces Differential Expression Signatures Of Inflammatory Molecules During Dendritic Cell Differentiation And Maturation, Martin Oaks, Nathaniel Rein, John O. Richards, James Shaffer
Journal of Patient-Centered Research and Reviews
Purpose: We tested the hypothesis that different glycoforms of antibodies from patients with metastatic melanoma have different functional effects on human dendritic cell differentiation and maturation.
Methods: Antibodies to the cancer antigen NY-ESO-1 were affinity-purified from patients with melanoma and further fractionated into different glycoforms by lectin chromatography. Sialic acid-rich and sialic acid-poor fractions of these immunoglobulin G antibodies (IgG) were added to dendritic cell cultures during both differentiation and maturation, and the resulting cellular messenger RNA (mRNA) and culture supernatants were tested by microarray and enzyme-linked immunoassay for molecules related to inflammatory pathways.
Results: We identified unique mRNA and …
Melanoma: Attacking On Many Fronts, Michael A. Thompson
Melanoma: Attacking On Many Fronts, Michael A. Thompson
Journal of Patient-Centered Research and Reviews
No abstract provided.
Targeted Therapy For Cutaneous Melanoma: Beyond Braf..., Michael A. Davies
Targeted Therapy For Cutaneous Melanoma: Beyond Braf..., Michael A. Davies
Journal of Patient-Centered Research and Reviews
The development and regulatory approval of vemurafenib and dabrafenib for metastatic melanoma patients with activating BRAF mutations has demonstrated that personalized targeted therapy strategies can provide significant clinical benefit in this highly aggressive disease. However, these agents are not beneficial in patients who do not have activating BRAF mutations, representing over half of all melanoma patients. Recent studies have demonstrated that melanomas have the highest rate of somatic mutations among the major cancers. Based on this information, additional personalized treatment strategies are now in various stages of clinical development and testing. These efforts are being guided by the lessons learned …
The Molecular Biology And Treatment Of Malignant Melanoma With Brafv600 Mutations, Michael P. Mullane
The Molecular Biology And Treatment Of Malignant Melanoma With Brafv600 Mutations, Michael P. Mullane
Journal of Patient-Centered Research and Reviews
Since 2011, the treatment options for metastatic malignant melanoma have significantly changed. In that year, ipilimumab, an anti-CTLA4 monoclonal antibody, and vemurafenib, a potent inhibitor of mutated-BRAF (V600E and V600K), were approved by the U.S. Food and Drug Administration (FDA). In 2013, dabrafenib, another inhibitor of mutated-BRAF, and trametinib, a MEK inhibitor, were approved by the FDA. Most recently, combination therapy with dabrafenib and trametinib was approved. This article will describe a patient with metastatic malignant melanoma with BRAFV600E who has responded very well to vemurafenib monotherapy. We will then explore the molecular basis, pharmacologic development and clinical outcomes …
Sentinel Lymph Node Biopsy In Head And Neck Melanoma: A Review, Martin Corsten, Stephanie Johnson-Obaseki
Sentinel Lymph Node Biopsy In Head And Neck Melanoma: A Review, Martin Corsten, Stephanie Johnson-Obaseki
Journal of Patient-Centered Research and Reviews
The incidence of melanoma in the United States continues to rise. Head and neck melanomas comprise approximately 20% of all primary cutaneous melanomas. Sentinel lymph node (SLN) biopsy (SLNB) has become the standard of care for staging in melanoma. It has a number of advantages, including the addition of prognostic information, accurate staging, and the potential to add completion lymph node dissection (CLND) or adjuvant therapy when indicated. Furthermore, it may allow for the identification of patients who would benefit from inclusion in clinical trials; this advantage may be amplified based on the introduction of novel targeted therapies.
SLNB does …
A Rendezvous With An Unexpected Diagnosis, Helen C. Williams, Alexandria Rogers
A Rendezvous With An Unexpected Diagnosis, Helen C. Williams, Alexandria Rogers
Journal of Patient-Centered Research and Reviews
A personal account of skin cancer explores a caregiver’s emotional encounter with malignant melanoma, following her podiatrist’s initial diagnosis when she presented for an ingrown toenail.
Primary Care For Melanoma: Should We Be Screaming For Screening?, Dennis J. Baumgardner, Alexandria Rogers
Primary Care For Melanoma: Should We Be Screaming For Screening?, Dennis J. Baumgardner, Alexandria Rogers
Journal of Patient-Centered Research and Reviews
The incidence of cutaneous malignant melanoma continues to rise in the United States. This deadly disease is potentially curable if caught at an early stage, however screening programs remain controversial. The United States Preventive Services Task Force cites insufficient evidence to recommend screening, by total-body skin examination (TBSE), for early detection of cutaneous melanoma. While definitive studies may be cost-prohibitive in the United States, more recent evidence suggests that organized programs to increase TBSE reduce mortality from melanoma. The positive impact of TBSE, and education regarding risk reduction and skin self-examination, is most likely to be cost-effective in high-risk patients …